Compare FirstEnergy Corp. (FE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs State Street SPDR S&P Biotech ETF — how do they compare? FirstEnergy Corp. trades at $44.9 (market cap $25.80B), while State Street SPDR S&P Biotech ETF trades at $149.81 (market cap $10.08B). The key difference: FirstEnergy Corp. is far larger — about 2.6× State Street SPDR S&P Biotech ETF's market cap, and FirstEnergy Corp. pays a 4.17% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold FirstEnergy Corp. for 71 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| FE | XBI | |
|---|---|---|
Market Cap | $25.80B | $10.08B |
Volume | 5,328,616 | 9,534,635 |
Sector | Utilities | Broad Market / Factor |
52-Week High | $51.91 | $169.55 |
52-Week Low | $43.04 | $104.99 |
Typical Hold Time | 71 Days | 37 Days |
Enterprise Value | $54.72B | — |
Dividend Yield | 4.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $44.85, up 1.33% with mixed technical signals showing bullish overall but bearish moving averages. The company reported Q1 2026 EPS beat but missed Q4 2025 and Q2 2026 expectations, with Q3 2026 results pending. Revenue grew to $15.09B in 2025 with stable profit margins around 6.86%. Recent developments include the $36B Energize365 investment plan and consistent dividend payments, supporting long-term growth prospects in the utility sector.
FE presents a moderate buy opportunity with analyst consensus target of $52.80 offering 17.7% upside. Strong institutional interest and dividend stability balance execution risks from heavy capital expenditures and debt levels. The stock's valuation appears reasonable with P/E of 23.84, though investors should monitor earnings consistency and regulatory developments in the electric utility space.
XBI trades at $150.23, down 0.44% on the day, with bearish technical signals dominating. The ETF faces resistance near $152-154 while finding support at $147-149 levels. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech sector optimism from M&A activity and cancer vaccine breakthroughs. The fund's 0.35% expense ratio compares unfavorably to broader healthcare ETFs but offers targeted biotech exposure.
Outlook remains mixed with technical weakness offset by sector catalysts. The biotech focus provides growth potential but carries higher volatility than diversified healthcare alternatives. Key risks include sector-specific regulatory pressures and the fund's expense structure, while opportunities exist from ongoing pharmaceutical innovation and capital market improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
